Minimal effects of Darunavir on adipocyte differentiation and metabolism in 3T3-L1 cells.
Darunavir (DRV) has been confirmed to be an effective option for antiretroviral-naïve and experienced patients. It results in a more favorable lipid and glucose profile than other antiretrovirals. The objective of this study was to investigate the molecular mechanisms that could underline the lack of toxicity of DRV to metabolism and the better profile observed in HIV-infected patients in comparison with other drugs. The effects of DRV on adipogenesis were evaluated by oil red O staining after 8 days of induction of differentiation in 3T3-L1 cells, a very adequate and convenient cell culture model for investigation of adipose function. Several adipogenic genes (C/EBPα, PPARγ, Pref-1, and AP2) were analyzed by real time-PCR. Fully differentiated adipocytes were also incubated with DRV for 24 h and glucose utilization and lactate and glycerol production were quantified by use of an autoanalyzer. No effects of DRV on murine adipocyte differentiation were observed. Significant decreases in lipolysis, glucose uptake, and lactate production were observed at the highest concentration used (50 μM:) (p < 0.01-p < 0.001). However, DRV treatment did not modify the percentage of glucose transformed into lactate. Co-treatment with RTV did not induce any further effects on lipolysis and glucose metabolism. This study suggests that the decrease in lipolysis observed after DRV treatment could explain, at least in part, the lower plasma lipids observed in patients under DRV/r treatment in comparison with other drugs. The lack of effects of RTV co-treatment on glucose and lipid metabolism emphasizes the safety of this treatment.